The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The combined debt and equity financing for the Washington state allergy lab comes as demand for food-related allergy testing is growing.
The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.
The companies will bring NIPD Genetics' Veracity and Veragene noninvasive prenatal tests to Medicover's markets, as well as developing new genetic tests.
The funding will support efforts to convert PGDx's technology, including both tissue and liquid biopsy tests, for dissemination as regulated IVD kits.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
NewStem is developing a technology that uses human haploid embryonic stem cells to predict cancer drug resistance.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The financing will be used to hire additional team members and conduct additional studies in fertility science. The firm also launched its $199 fertility test.
Illumina Ventures was the sole investor in the Series A1 round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay.